Global Shigella Infections (Shigellosis) Clinical Trials Review Market Analysis Report 2015 Radiant Insights, Inc
Summary Radiant Insights's clinical trial report, "Shigella Infections (Shigellosis) Global Clinical Trials Review, H1, 2015" provides data on the Shigella Infections (Shigellosis) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Shigella Infections (Shigellosis). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Shigella Infections (Shigellosis). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Radiant Insights's team of industry experts. Read Complete Report with TOC @ http://www.radiantinsights.com/research/shigella-infections-shigellosis-global-clinical-trials-review-h1-2015 Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reason to Buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Summary
Radiant Insights's clinical trial report, "Shigella Infections (Shigellosis) Global Clinical Trials Review, H1, 2015" provides data on the Shigella Infections (Shigellosis) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Shigella Infections (Shigellosis). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Shigella Infections (Shigellosis). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Radiant Insights's team of industry experts.
Read Complete Report with TOC @ http://www.radiantinsights.com/research/shigella-infections-shigellosis-global-clinical-trials-review-h1-2015
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)
Reason to Buy
- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Global</strong> <strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) <strong>Clinical</strong> <strong>Trials</strong> <strong>Review</strong><br />
<strong>Market</strong> <strong>Analysis</strong> <strong>Report</strong> <strong>2015</strong>: <strong>Radiant</strong> <strong>Insights</strong>, <strong>Inc</strong><br />
Summary<br />
<strong>Radiant</strong> <strong>Insights</strong>'s clinical trial report, "<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) <strong>Global</strong> <strong>Clinical</strong> <strong>Trials</strong><br />
<strong>Review</strong>, H1, <strong>2015</strong>" provides data on the <strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) clinical trial scenario. This<br />
report provides elemental information and data relating to the clinical trials on <strong>Shigella</strong> <strong>Infections</strong><br />
(<strong>Shigellosis</strong>). It includes an overview of the trial numbers and their recruitment status as per the site of<br />
trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials<br />
by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the<br />
number of trials for the key drugs for treating <strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>). This report is built<br />
using data and information sourced from proprietary databases, primary and secondary research and<br />
in-house analysis by <strong>Radiant</strong> <strong>Insights</strong>'s team of industry experts.<br />
Read Complete <strong>Report</strong> with TOC @ http://www.radiantinsights.com/research/shigellainfections-shigellosis-global-clinical-trials-review-h1-<strong>2015</strong><br />
Scope<br />
- Data on the number of clinical trials conducted in North America, South and Central America,<br />
Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each<br />
- <strong>Clinical</strong> trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor<br />
type<br />
- Listings of discontinued trials (suspended, withdrawn and terminated)<br />
Reason to Buy<br />
- Understand the dynamics of a particular indication in a condensed manner<br />
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor<br />
type and many more<br />
- Obtain discontinued trial listing for trials across the globe<br />
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies<br />
Table of Contents<br />
Table of Contents 2<br />
List of Tables 3<br />
List of Figures 4
Introduction 5<br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) 5<br />
<strong>Report</strong> Guidance 5<br />
<strong>Clinical</strong> <strong>Trials</strong> by Region 6<br />
<strong>Clinical</strong> <strong>Trials</strong> and Average Enrollment by Country 7<br />
Top Countries Contributing to <strong>Clinical</strong> <strong>Trials</strong> in Asia-Pacific 9<br />
Top Countries Contributing to <strong>Clinical</strong> <strong>Trials</strong> in Europe 10<br />
Top Countries Contributing to <strong>Clinical</strong> <strong>Trials</strong> in North America 11<br />
Top Countries Contributing to <strong>Clinical</strong> <strong>Trials</strong> in Middle East and Africa 12<br />
<strong>Clinical</strong> <strong>Trials</strong> by G7 Countries: Proportion of <strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) to Infectious Disease<br />
<strong>Clinical</strong> <strong>Trials</strong> 13<br />
<strong>Clinical</strong> <strong>Trials</strong> by Phase in G7 Countries 14<br />
Read Complete <strong>Report</strong> with TOC @ http://www.radiantinsights.com/research/shigellainfections-shigellosis-global-clinical-trials-review-h1-<strong>2015</strong><br />
<strong>Clinical</strong> <strong>Trials</strong> in G7 Countries by Trial Status 15<br />
<strong>Clinical</strong> <strong>Trials</strong> by Phase 16<br />
<strong>Clinical</strong> <strong>Trials</strong> by Trial Status 17<br />
<strong>Clinical</strong> <strong>Trials</strong> by End Point Status 18<br />
Unaccomplished <strong>Trials</strong> of <strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) 19<br />
Subjects Recruited Over a Period of Time 21<br />
<strong>Clinical</strong> <strong>Trials</strong> by Sponsor Type 22<br />
Prominent Sponsors 23<br />
Top Companies Participating in <strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics <strong>Clinical</strong> <strong>Trials</strong> 24<br />
Prominent Drugs 25<br />
<strong>Clinical</strong> Trial Profiles 26<br />
<strong>Clinical</strong> Trial Overview of Top Companies 26<br />
GlaxoSmithKline plc 26<br />
<strong>Clinical</strong> Trial Overview of GlaxoSmithKline plc 26<br />
Novartis AG 27
<strong>Clinical</strong> Trial Overview of Novartis AG 27<br />
Icddr,b 28<br />
<strong>Clinical</strong> Trial Overview of Icddr,b 28<br />
<strong>Clinical</strong> Trial Overview of Top Institutes / Government 29<br />
Eunice Kennedy Shriver National Institute of Child Health and Human Development 29<br />
<strong>Clinical</strong> Trial Overview of Eunice Kennedy Shriver National Institute of Child Health and Human<br />
Development 29<br />
University of Maryland 30<br />
<strong>Clinical</strong> Trial Overview of University of Maryland 30<br />
Institut Pasteur 31<br />
<strong>Clinical</strong> Trial Overview of Institut Pasteur 31<br />
PATH 32<br />
<strong>Clinical</strong> Trial Overview of PATH 32<br />
Read Complete <strong>Report</strong> with TOC @ http://www.radiantinsights.com/research/shigellainfections-shigellosis-global-clinical-trials-review-h1-<strong>2015</strong><br />
U.S. Army Medical Research and Materiel Command 33<br />
<strong>Clinical</strong> Trial Overview of U.S. Army Medical Research and Materiel Command 33<br />
U.S. Department of Defense 34<br />
<strong>Clinical</strong> Trial Overview of U.S. Department of Defense 34<br />
University of Maryland, Baltimore 35<br />
<strong>Clinical</strong> Trial Overview of University of Maryland, Baltimore 35<br />
University of Oxford 36<br />
<strong>Clinical</strong> Trial Overview of University of Oxford 36<br />
Five Key <strong>Clinical</strong> Profiles 37<br />
Appendix 60<br />
Abbreviations 60<br />
Definitions 60<br />
Research Methodology 61<br />
Secondary Research 61
About <strong>Global</strong>Data 62<br />
Contact Us 62<br />
Disclaimer 62<br />
Source 62<br />
List of Tables<br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Region, <strong>2015</strong>* 6<br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> and Average Enrollment by Top<br />
Countries, <strong>2015</strong>* 7<br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> In Progress by Top Countries,<br />
<strong>2015</strong>* 8<br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, Asia-Pacific, Top Countries, <strong>2015</strong>* 9<br />
Read Complete <strong>Report</strong> with TOC @ http://www.radiantinsights.com/research/shigellainfections-shigellosis-global-clinical-trials-review-h1-<strong>2015</strong><br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, Europe, Top Countries, <strong>2015</strong>* 10<br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, North America, Top Countries, <strong>2015</strong>*<br />
11<br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, Middle East and Africa, Top Countries,<br />
<strong>2015</strong>* 12<br />
Proportion of <strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) to Infectious Disease <strong>Clinical</strong> <strong>Trials</strong>, G7 Countries (%),<br />
<strong>2015</strong>* 13<br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics, G7 Countries, <strong>Clinical</strong> <strong>Trials</strong> by Phase, <strong>2015</strong>* 14<br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics, G7 Countries, <strong>Clinical</strong> <strong>Trials</strong> by Trial Status, <strong>2015</strong>* 15<br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Phase, <strong>2015</strong>* 16<br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Trial Status, <strong>2015</strong>* 17<br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, <strong>Global</strong>, by End Point Status, <strong>2015</strong>* 18<br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics, <strong>Global</strong>, Withdrawn <strong>Clinical</strong> <strong>Trials</strong>, <strong>2015</strong>* 19<br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics, <strong>Global</strong>, Terminated <strong>Clinical</strong> <strong>Trials</strong>, <strong>2015</strong>* 20<br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, <strong>Global</strong>, Average Enrollment Target<br />
Trends, 2010-2014 21
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Sponsor Type, <strong>2015</strong>*<br />
22<br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, <strong>Global</strong>, Key Sponsors, <strong>2015</strong>* 23<br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, <strong>Global</strong>, Top Companies by Phase,<br />
<strong>2015</strong>* 24<br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, <strong>Global</strong>, Ongoing <strong>Clinical</strong> <strong>Trials</strong> by<br />
Prominent Drugs, <strong>2015</strong>* 25<br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by<br />
GlaxoSmithKline plc, <strong>2015</strong>* 26<br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by<br />
Novartis AG, <strong>2015</strong>* 27<br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by<br />
Icddr,b, <strong>2015</strong>* 28<br />
Read Complete <strong>Report</strong> with TOC @ http://www.radiantinsights.com/research/shigellainfections-shigellosis-global-clinical-trials-review-h1-<strong>2015</strong><br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by<br />
Eunice Kennedy Shriver National Institute of Child Health and Human Development, <strong>2015</strong>* 29<br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by<br />
University of Maryland, <strong>2015</strong>* 30<br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by<br />
Institut Pasteur, <strong>2015</strong>* 31<br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by<br />
PATH, <strong>2015</strong>* 32<br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by U.S.<br />
Army Medical Research and Materiel Command, <strong>2015</strong>* 33<br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by U.S.<br />
Department of Defense, <strong>2015</strong>* 34<br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by<br />
University of Maryland, Baltimore, <strong>2015</strong>* 35<br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by<br />
University of Oxford, <strong>2015</strong>* 36<br />
List of Figures<br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Region (%), <strong>2015</strong>* 6
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> and Average Enrollment by Top<br />
Countries, <strong>2015</strong>* 7<br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> In Progress by Top Countries,<br />
<strong>2015</strong>* 8<br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, Asia-Pacific, Top Countries (%), <strong>2015</strong>*<br />
9<br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, Europe, Top Countries (%), <strong>2015</strong>* 10<br />
Proportion of <strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) to Infectious Disease <strong>Clinical</strong> <strong>Trials</strong>, G7 Countries (%),<br />
<strong>2015</strong>* 13<br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics, G7 Countries, <strong>Clinical</strong> <strong>Trials</strong> by Phase, <strong>2015</strong>* 14<br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics, G7 Countries, <strong>Clinical</strong> <strong>Trials</strong> by Trial Status, <strong>2015</strong>* 15<br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Phase (%), <strong>2015</strong>* 16<br />
Read Complete <strong>Report</strong> with TOC @ http://www.radiantinsights.com/research/shigellainfections-shigellosis-global-clinical-trials-review-h1-<strong>2015</strong><br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Trial Status, <strong>2015</strong>* 17<br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, <strong>Global</strong>, by End Point Status, <strong>2015</strong>* 18<br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, <strong>Global</strong>, Average Enrollment Target<br />
Trends, 2010-2014 21<br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Sponsor Type (%),<br />
<strong>2015</strong>* 22<br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, <strong>Global</strong>, Key Sponsors, <strong>2015</strong>* 23<br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, <strong>Global</strong>, Top Companies by Phase,<br />
<strong>2015</strong>* 24<br />
<strong>Shigella</strong> <strong>Infections</strong> (<strong>Shigellosis</strong>) Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, <strong>Global</strong>, Ongoing <strong>Clinical</strong> <strong>Trials</strong> by<br />
Prominent Drugs, <strong>2015</strong>* 25<br />
About <strong>Radiant</strong> <strong>Insights</strong><br />
<strong>Radiant</strong> <strong>Insights</strong> is a platform for companies looking to meet their market research and business<br />
intelligence requirements. We assist and facilitate organizations and individuals procure market<br />
research reports, helping them in the decision making process. We have a comprehensive collection of<br />
reports, covering over 40 key industries and a host of micro markets. In addition to over extensive<br />
database of reports, our experienced research coordinators also offer a host of ancillary services such<br />
as, research partnerships/ tie-ups and customized research solutions.<br />
For More Information, Visit <strong>Radiant</strong> <strong>Insights</strong>
Contact:<br />
Michelle Thoras<br />
Corporate Sales Specialist, USA<br />
<strong>Radiant</strong> <strong>Insights</strong>, <strong>Inc</strong><br />
Phone: 1-415-349-0054<br />
Toll Free: 1-888-202-9519<br />
Email: sales@radiantinsights.com<br />
Blog URL: http://www.radiantinsightsinc.blogspot.com
Change language